CULLINAN THERAPEUTICS, INC. (CGEM) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$57.17M*; Operating income -$57.25M; Depreciation and amortization $79.00K*.
- 2026-03-31: Basis Reported; EBITDA -$53.62M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$55.18M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$55.52M*; Operating income -$55.59M; Depreciation and amortization $79.00K*.
Complete source-backed ebitda history.
- Available history
- 2020-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$57.17M* | -$57.25M | $79.00K* | (m) | (m) | (m) | -$38.22M* | (m) | $44.44M | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$53.62M | (m) | (m) | (m) | (m) | (m) | -$46.05M | (m) | $42.12M | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$55.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$55.52M* | -$55.59M | $79.00K* | (m) | (m) | (m) | -$36.88M* | (m) | $41.97M | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$75.72M* | -$75.80M | $77.00K* | (m) | (m) | (m) | -$57.61M* | (m) | $61.03M | (m) | (m) |
|---|
| 2025-03-31 | Reported | -$54.92M | (m) | (m) | (m) | (m) | (m) | -$43.16M | (m) | $41.46M | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$54.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$48.78M* | -$48.85M | $76.00K* | (m) | (m) | $0.00* | -$34.14M* | (m) | $35.51M | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$49.95M* | -$50.03M | $77.00K* | (m) | (m) | $0.00* | -$36.29M* | (m) | $36.26M | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$42.91M | (m) | (m) | (m) | (m) | $0.00 | -$38.25M | (m) | $30.65M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$45.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$45.16M* | -$45.24M | $80.00K* | (m) | (m) | $0.00* | -$34.14M* | (m) | $33.82M | (m) | $0.00 |
|---|
| 2023-06-30 | Reported | -$37.52M* | -$37.60M | $81.00K* | (m) | (m) | $49.00K* | -$31.01M* | (m) | $27.39M | (m) | $0.00 |
|---|
| 2023-03-31 | Reported | -$62.68M | (m) | (m) | (m) | (m) | $159.00K | -$51.00M | (m) | $52.10M | (m) | $0.00 |
|---|
| 2022-12-31 | Reported | -$32.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$29.76M* | -$29.77M | $9.00K* | $0.00 | (m) | $251.00K* | -$54.35M* | (m) | $19.68M | (m) | -$2.52M |
|---|
| 2022-06-30 | Reported | $239.69M* | $239.68M | $12.00K* | $0.00 | (m) | $0.00* | -$25.42M* | (m) | $26.41M | (m) | $66.07M |
|---|
| 2022-03-31 | Reported | -$32.64M | (m) | (m) | (m) | (m) | $0.00 | -$21.91M | (m) | $24.54M | (m) | -$19.57M |
|---|
| 2021-12-31 | Reported | -$34.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$18.36M* | -$18.38M | $13.00K* | $0.00 | (m) | (m) | -$10.55M* | (m) | $12.68M | (m) | $0.00 |
|---|
| 2021-06-30 | Reported | -$16.59M* | -$16.60M | $13.00K* | $0.00 | (m) | (m) | -$16.20M* | (m) | $11.78M | (m) | $0.00 |
|---|
| 2021-03-31 | Reported | $1.39M | (m) | (m) | (m) | 7.32% | (m) | -$1.51M | (m) | $12.41M | (m) | $0.00 |
|---|
| 2020-12-31 | Reported | -$29.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$11.48M* | -$11.50M | $15.00K* | (m) | (m) | $4.00K* | -$9.07M* | (m) | $9.91M | (m) | $0.00 |
|---|
| 2020-06-30 | Reported | -$14.11M* | -$14.12M | $16.00K* | (m) | (m) | $4.00K* | -$6.25M* | (m) | $12.50M | (m) | $0.00 |
|---|
| 2020-03-31 | Reported | -$5.53M | (m) | (m) | (m) | (m) | $3.00K | -$5.01M | (m) | $4.17M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$241.34M | (m) | (m) | (m) | (m) | $49.00K | -$175.75M | (m) | $187.40M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$196.61M | (m) | (m) | (m) | (m) | $0.00 | -$145.30M | (m) | $142.90M | (m) | $117.00K |
|---|
| 2023-12-31 | Reported | -$190.78M | (m) | (m) | (m) | (m) | $208.00K | -$134.28M | (m) | $148.16M | (m) | -$14.12M |
|---|
| 2022-12-31 | Reported | $144.74M | (m) | (m) | (m) | (m) | $1.13M | -$126.66M | (m) | $91.95M | (m) | $42.12M |
|---|
| 2021-12-31 | Reported | -$67.9M | (m) | (m) | (m) | -358.45% | $0.00 | -$43.43M | (m) | $57.75M | (m) | $0.00 |
|---|
| 2020-12-31 | Reported | -$60.27M | (m) | (m) | (m) | (m) | $10.00K | -$29.77M | (m) | $43.21M | (m) | (m) |
|---|